WuXi PharmaTech And PRA Health Sciences Split Their China Clinical Stage JV

WuXi PharmaTech has split in two its clinical-stage China CRO JV with PRA Health Sciences of North Carolina. WuXi will take over control of the CRO's China operations, bringing them entirely in-house, and PRA will own the Hong Kong business. The two companies joined forces in 2013. PRA, a global CRO, added its China-based staff and global technology capabilities, including data capture, trial management and other IT systems. The current "restructuring," as it is being called, came at the request of WuXi.

Back to news